David J. Andorsky, MD, discusses treatment with tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma, highlighting updated outcomes from the phase 1b SYMPHONY-1 trial.
David J. Andorsky, MD, board-certified medical oncologist and hematologist at Rocky Mountain Cancer Centers, discussed findings from a study on patterns of Bruton tyrosine kinase (BTK) inhibitor care use and social determinants of health (SDOH) among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).